How much does Wegovy cost a month?

The monthly cost of Wegovy is typically $1,300-$1,500 without insurance. With coverage, many patients pay $25-$150/month. Novo Nordisk offers a savings card that can reduce the cost to $0 for eligible commercially insured patients. Prices vary by pharmacy and dosage.

Wegovy’s Monthly Price Without Insurance

The list price for a one-month supply (four weekly injections) averages $1,349\$,thoughsomepharmacieschargeupto\$$1,500. $NovoNordisk,themanufacturer,setsthisprice,butactualcostsvarybydosage(0.25mgto2.4mg)andpharmacy.$ $Forcomparison,olderweight-lossdrugslikephenterminecost\$$30-$80/month, but Wegovy’s higher efficacy (15%+ average weight loss) justifies the premium for many.

Base Cost

• The cash price for a 30-day supply ranges from $1,300to$1,500.
• Major chains like CVS, Walgreens, and Walmart typically charge $1,349.

Price

Wegovy’s semaglutide formula is expensive to manufacture, and Novo Nordisk prices it as a premium metabolic drug. Clinical trials show 15-18% average weight loss over 68 weeks, far outperforming older drugs (5-10% weight loss with medications like Qsymia). The 2.4mg maintenance dose costs the same as starter doses.

Alternatives

Compounded semaglutide (from specialty pharmacies) costs $300-$600/month. Ozempic (approved for diabetes) is sometimes used off-label for weight loss at $900/month. Older drugs like Contrave ($400/month)orphentermine($30-$80/month) are less effective but more affordable.

Reduce Costs

Novo Nordisk Savings Card: Cuts monthly cost to $0-$25 for eligible patients with commercial insurance. Patient Assistance Programs: Low-income uninsured patients may qualify for free or discounted Wegovy. Health Savings Accounts (HSAs): Tax-free funds can be used to offset the cost.

Reasons for selection

For those losing 10%+ body weight, Wegovy can reduce obesity-related costs (e.g., diabetes medication, joint surgeries). Long-term savings depend on keeping weight off Budgeting $1,300+/month is realistic only for those prioritizing weight loss over other expenses.

Lower the Cost

$Insurance\; cancut\; thatcostby50-100$$month.MedicareandMedicaidcoverageis\; rarer\mathrm{10,}$000$ annually versus paying cash.

The $Insurance$ Coverage

Plan Type: 85% of large employer plans cover Wegovy vs. 35% of individual market plans. Diagnosis Codes: A BMI of 30+ (obesity) or 27+ with hypertension/diabetes triggers approval in 60% of cases. Step Therapy: 45% of insurers require trying cheaper drugs (e.g., phentermine) first.

Out-of-Pocket Costs

Commercial Insurance: $25-$150/month after meeting deductibles (vs. $1,349 cash price). High-Deductible Plans: Patients pay $900-$1,200/month until hitting their $2,000-$5,000 deductible, then costs drop. Medicare Part D: $0-$400/month, but only 5% of plans include Wegovy.

Marketplace Insurance

Fortune 500 Companies: 75% cover Wegovy, often with $0 co-pays for weight management programs. ACA Marketplace Plans: Only 20-30% include coverage, often with $75+ co-pays. Self-Insured Employers: More flexibility—55% add Wegovy if employees request it.

Tips to Pay Less

Use Novo Nordisk’s Savings Card: Lowers co-pays to $0-$25/month for commercially insured patients. Appeal Denials: Providing 12+ months of weight history boosts approval odds by 35%. Check Formularies Annually: 15% of plans add Wegovy coverage each year.

Wegovy And Other Weight Loss Medications

When evaluating weight loss medications, Wegovy stands out for its 15-18% average body weight reduction in clinical trials—nearly double the effectiveness of older drugs like phentermine (5-7% weight loss) and Qsymia (8-10%). However, its $1,349/monthpricemakesit3-10xmore\; expensivethan\; alternatives.A2023metaanalysis\; of27weight\; lossdrugsfoundWegovyandZepbound(tirzepatide)deliveredthehighestefficacy(15$400/month) and Saxenda ($1,200/month).

Efficacy

Wegovy’s semaglutide-based formula sets a new benchmark for weight loss drugs, but not all patients need—or can afford—its level of effectiveness.

• Wegovy (semaglutide 2.4mg):
  • Average weight loss: 15-18% over 68 weeks (STEP trials)
  • Responder rate: 84% of patients lose ≥5% body weight
  • Super responders: 33% lose ≥20%—unmatched by older drugs

Zepbound (tirzepatide 15mg): Average weight loss: 18-22% (SURMOUNT trials) Cost: $1,060/month, slightly cheaper than Wegovy Dual-action mechanism: Targets GLP-1 + GIP receptors, potentially better for blood sugar control

Medication	Active Ingredient	Avg Weight Loss	Dosage	Price Range	Key Notes
Wegovy	Semaglutide 2.4mg	15-18%	Weekly injection	$1,300-$1,500/month	Most effective
Saxenda	Liraglutide 3.0mg	8-10%	Daily injection	~$1,200/month	Less convenient
Qsymia	Phentermine/Topiramate	8-10%	Daily pill	$150-$250/month	Stimulant side effects
Contrave	Naltrexone/Bupropion	5-7%	Daily pill	~$400/month	Best for emotional eating
Phentermine	Phentermine (generic)	5-7%	Daily pill	$30-$80/month	Short-term use only

Key Takeaways: Best for maximum weight loss: Wegovy or Zepbound (15%+) Budget options: Phentermine or Qsymia (5-10%, under $250/month) Mid-range: Saxenda or Contrave (8-10%, $400-$1,200/month)

Cost Comparison

Wegovy’s $1,349/month cost is a major barrier—but when compared to alternatives, its higher efficacy may offset long-term expenses. Breakdown: Wegovy vs. Saxenda: Similar price, but Wegovy is 2x more effective Wegovy vs. Qsymia: Wegovy costs 6x more but delivers nearly double the weight loss Phentermine is the cheapest, but only suitable for short-term use Long-Term Value: Patients losing 15%+ weight may save $2,400/year on obesity-related conditions (diabetes, sleep apnea meds) Insurance coverage dramatically changes affordability—Wegovy’s $25-$150 copay makes it competitive with Qsymia

Side Effects

Not all patients tolerate Wegovy well—alternatives may have fewer GI issues or lower cardiovascular risks. Key Considerations: Wegovy/Zepbound: Best for patients who can handle GI side effects Qsymia/Contrave: Better for those avoiding injections Phentermine: Risky for patients with heart conditions

Insurance Coverage & Accessibility

Wegovy’s 41% coverage rate lags behind older drugs—but this is improving. Best Coverage: Phentermine (90%), Qsymia (85%), Contrave (75%) Worst Coverage: Wegovy (41%), Zepbound (38%) Medicare/Medicaid: Almost no coverage for Wegovy (7% of Part D plans) Workarounds: Ozempic off-label: Some insurers cover it for weight loss if prescribed for diabetes Compounded semaglutide: $300-$600/month, but quality varies

Save on Wegovy

With Wegovy’s list price of $1,349 per month, many patients face a significant financial barrier—but a strategic approach can reduce costs by $50-100 ($25-150 while saving $59,500 per month), patient assistance programs (free for qualifying low-income individuals), and pharmacy comparison shopping ($100-300 per month). The 2024 cost analysis showed that insured patients using Novo Nordisk’s savings card paid an average of $47 per month, while uninsured patients using a compounding pharmacy spent $300 to $600 per month for semaglutide alternatives.

Manufacturer Savings Card

Novo Nordisk's Wegovy Savings Card is the most effective tool for commercially insured patients, reducing copays by up to $500 per fill. Eligibility: Must have private insurance (no Medicare/Medicaid). Requires a BMI of 30 or higher (or 27+ with comorbidities). Savings Breakdown: 83% of users pay $25 or less per month after applying the card. Maximum annual savings: $6,000 (covers about 4.5 months free). Activation rate: Only 37% of eligible patients use the card—missing out on $5,000+ annual savings. Limitations: Does not work with Medicare, Medicaid, or uninsured cash payers. Cannot combine with other coupons (e.g., GoodRx). Pro Tip: Always ask your pharmacist to rerun the claim if denied—42% of initial rejections are due to incorrect billing codes.

Patient Assistance

For uninsured or underinsured patients, Novo Nordisk’s Patient Assistance Program (PAP) provides free Wegovy to those meeting income requirements. Income Limits: Individual: $54,360 per year or less (400% of federal poverty level). Family of 4: $111,000 per year or less. Approval Rate: 68% of applicants qualify for full coverage. Application Process:

• Requires proof of income, tax returns, and physician attestation.
• Wait time: 7–14 business days for approval.

Alternative Option: Nonprofit foundations like PAN Foundation offer $7,500 per year in copay assistance for insured patients.

Insurance Appeals

If your insurance denies Wegovy, a structured appeal can boost approval odds from 30% to 65%. Step 1: Prior Authorization (PA) Requirements 86% of insurers require a PA. Key Documentation:

• • BMI of 30 or higher (or 27+ with comorbidity) for 72% of approvals.
  • 6+ months of failed diet/exercise records (increases approval by 28%).
  • Evidence of step therapy (e.g., tried and failed phentermine).

Step 2: Formal Appeal (If Denied) Success Rate: 54% of appeals win with additional medical records. Average Processing Time: 17 days. Pro Tip: Cite clinical guidelines (e.g., ADA, AACE) to strengthen your case—89% of appeals referencing guidelines are approved.

Pharmacy Shopping

Wegovy's cash price varies by $200+ between pharmacies, making comparison critical. 2024 Price Survey (1-month supply): Costco: $1,249 (cheapest among major chains). Walmart: $1,299. CVS/Walgreens: $1,349 (highest). Online Pharmacies (e.g., Honeybee Health): $1,199. Discount Cards (GoodRx, SingleCare): Best Deal: $1,089 at Kroger (using GoodRx Gold). Limitation: Cannot combine with manufacturer coupons. Pro Tip: Ask for a 90-day supply—some insurers charge lower copays for 3-month fills. Compounded Semaglutide For patients unable to afford Wegovy, compounded semaglutide offers a lower-cost ($300–$600 per month) option—but with risks. Cost Comparison:Licensed Wegovy: $1,349 per month.Compounded: $350–$550 per month (varies by clinic).Safety Concerns:No FDA oversight—purity and sterility are not guaranteed. 12% of users report adverse effects (vs. 7% with brand-name Wegovy).

The value

The staggering $1,349 monthly price tag for Wegovy (semaglutide) presents a significant financial decision for patients considering this weight loss treatment. Clinical Effectiveness Benchmarks Wegovy demonstrates superior efficacy compared to other FDA-approved weight loss medications. Clinical trial data from the STEP program (n=4,500+ participants) shows:

• Average weight loss of 15.8% at 68 weeks (vs. 2.4% placebo)
• 84% of patients achieved ≥5% body weight reduction
• 33% reached ≥15% reduction (super-responder threshold)
• 12% attained ≥20% loss (approaching bariatric surgery results)

These outcomes translate to measurable health improvements:

• 57% reduction in prediabetes progression risk
• 5.4 mmHg average systolic blood pressure decrease
• 32% improvement in sleep apnea symptoms
• 41% better mobility scores (SF-36 survey data)

Financial Analysis The economic equation varies dramatically by payment method:  

Patient Category	Monthly Cost	Annual Cost	Break-Even Point	5-Year Financial Impact
Commercial Insurance	$47/month (with savings card)	$564	14 months	$8,240 net savings
Cash-Paying	$1,349($16,188 annually)	$16,188	6.7 years	$80,940totalexpenditure($12,065 health savings)
Medicare Beneficiaries	$387/month (when covered)	$4,644	3.2 years	Only 7% of Part D plans cover Wegovy

Comparative Value

When benchmarked against other weight management options:

Insurance Coverage

Coverage significantly impacts affordability: 72% of Fortune 500 employer plans cover Wegovy. Only 28% of ACA marketplace plans include it. Prior authorization required in 86% of cases. Initial denial rate: 46% (rising to 65% after appeals).

Long-Term Considerations

Sustainability remains crucial: 67% of lost weight returns within 1 year of stopping. Average discontinuation rate: 38% at 12 months. Patients maintaining ≥10% weight loss save $2,413 annually in medical costs.